INSTEM: FY 16A results: Solid performance ex-Clinical

Instem plc | Published on 13/04/2017

Instem’s FY 16A results were line with the Jan-17 trading update and our forecasts. Excluding the Clinical business, performance remains solid, particularly in pre-clinical and the SEND businesses. Management has taken decisive actions to address the weakness in Clinical and a further positive is the emerging services story. We make downward revisions to FY 17E earnings forecasts following the results reflecting additional investment in the business.

Download full analysis

Login to access research or Register now

Register now or

I confirm that I understand that research from Progressive Equity Research Limited is not intended for retail investors, and should not be relied upon in any decision-making process. It is published for the benefit of institutional investors only, and for the use of professional advisors in the course of their work. I acknowledge that, if I am a private investor, I will take advice from a registered financial advisor or stockbroker before making any investment decisions. I understand that equity investments carry significant risk, and that past performance is no guarantee of future performance. I acknowledge that neither Progressive Equity Research Limited, nor any of its directors or officers, accepts any liability with regard to the contents of this research, and that nothing within the research on this site constitutes a recommendation or solicitation to buy or sell shares.

Recent Analysis

INSTEM:  Solid interims

Published on 19/09/2016

INSTEM: Strategic step in Safety

Published on 08/09/2016

INSTEM: Samarind acquisition

Published on 02/06/2016

INSTEM: A day to remember

Published on 25/04/2016

INSTEM:  Strong FY15 results

Published on 05/04/2016

Archive